Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 1
Submit an article Journal homepage
225
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival

Sonia Gonzalez de Villambrosiaa Department of Hematology, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, SpainView further author information
,
Mariana Bastosb Department of Hematology, Hospital Universitario Gregorio Marañón, Madrid, SpainView further author information
,
Javier Menarguez Palancac Department of Anatomic Pathlogy, Hospital Universitario Gregorio Marañón, Madrid, SpainView further author information
,
Jorge Gayoso Cruzb Department of Hematology, Hospital Universitario Gregorio Marañón, Madrid, SpainView further author information
,
José-Tomás Navarrod Department of Hematology, ICO-Badalona, Germans Trias i Pujol, Badalona, SpainView further author information
,
Gustavo Tapiae Department of Anatomic Pathology, Hospital Germans Trias i Pujol, Universidad Autónoma de Barcelona, Badalona, SpainView further author information
,
Sara Alvarez Alonsof Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, SpainView further author information
,
Alejandro Martinf Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, SpainView further author information
,
Oscar Blancog Department of Anatomic Pathology, Hospital Clinico Universitario Salamanca, IBSAL, Salamanca, SpainView further author information
,
Pau Abrisquetah Department of Hematology, Hospital Universitari Vall d’Hebron, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainView further author information
,
Josep Castellvii Department of Anatomic Pathology, Hospital Universitari Vall d’Hebron, Barcelona, SpainView further author information
,
Ana García-Noblejasj Department of Hematology, Hospital Universitario de La princesa, Madrid, SpainView further author information
,
Reyes Arranzj Department of Hematology, Hospital Universitario de La princesa, Madrid, SpainView further author information
,
Magdalena Adradosk Department of Anatomic Pathology, Hospital Universitario de La Princesa, Madrid, SpainView further author information
,
Andrés Lópezh Department of Hematology, Hospital Universitari Vall d’Hebron, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainView further author information
,
Santiago Montes-Morenol Department of Anatomic Pathology, Hospital Universitario Marqués de Valdecilla. Translational Hematopathology Lab, IDIVAL, UNICAN, Santander, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3565-8262View further author information
ORCID Icon & On behalf of Grupo Español de linfomas y trasplante (GELTAMO) show all
Pages 101-108 | Received 09 Feb 2021, Accepted 24 Aug 2021, Published online: 11 Sep 2021

References

  • Swerdlow SH, Campo E, Harris NL, (eds). et al. WHO classification of tumours of haematopoietic and lymphoid tissues. revised 4th ed. Lyon: IARC; 2017.
  • Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319–2331.
  • Perry AM, Crockett D, Dave BJ, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol. 2013;162(1):40–49.
  • Rosenwald A, Bens S, Advani R, et al. Prognostic significance of. J Clin Oncol. 2019;37(35):3359–3368.
  • Copie-Bergman C, Cuillière-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126(22):2466–2474.
  • Pedersen M, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92(1):42–48.
  • Aukema SM, Kreuz M, Kohler CW, et al.; Molecular Mechanisms in Malignant Lymphomas Network Project. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular burkitt lymphoma. Haematologica. 2014;99(4):726–735.
  • Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
  • Hu SM, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood. 2013;121(20):4021–4031.
  • Ribera JM, García O, Grande C, et al. Dose-intensive chemotherapy including rituximab in burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (burkimab). Cancer. 2013;119(9):1660–1668.
  • Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD anderson cancer center clinical experience. Br J Haematol. 2014;166(6):891–901.
  • Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182–2188.
  • Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–340.
  • Visco C, Tzankov A, Xu-Monette ZY, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an international DLBCL rituximab-CHOP consortium program study. Haematologica. 2013;98(2):255–263.
  • Purroy N, Bergua J, Gallur L, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the spanish PETHEMA group. Br J Haematol. 2015;169(2):188–198.
  • Cucco F, Barrans S, Sha C, et al. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Leukemia. 2020;34(5):1329–1341.
  • Ennishi D, Jiang A, Boyle M, et al. Double-Hit gene expression signature defines a distinct subgroup of germinal center B-Cell-Like diffuse large B-Cell lymphoma. J Clin Oncol. 2019;37(3):190–201.
  • Hilton LK, Tang J, Ben-Neriah S, et al. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019;134(18):1528–1532.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.